HIV/AIDS in Practice An Expert Commentary with Myron Cohen, MD A - - PowerPoint PPT Presentation

hiv aids in practice an expert commentary with myron
SMART_READER_LITE
LIVE PREVIEW

HIV/AIDS in Practice An Expert Commentary with Myron Cohen, MD A - - PowerPoint PPT Presentation

HIV/AIDS in Practice An Expert Commentary with Myron Cohen, MD A Clinical Context Report Clinical Context: HIV/AIDS in Practice Expert Commentary Jointly Sponsored by: and Clinical Context: HIV/AIDS in Practice Expert Commentary This


slide-1
SLIDE 1

HIV/AIDS in Practice An Expert Commentary with Myron Cohen, MD A Clinical Context Report

slide-2
SLIDE 2

Jointly Sponsored by: and

Clinical Context: HIV/AIDS in Practice Expert Commentary

slide-3
SLIDE 3

This activity is supported by an independent educational grant from Abbott.

Clinical Context: HIV/AIDS in Practice Expert Commentary

slide-4
SLIDE 4

HIV/AIDS in Practice Clinical Context Series The goal of this series is to provide up-to- date information and multiple perspectives

  • n the pathogenesis, symptoms, risk

factors, and complications of HIV/AIDS, as well as current and emerging treatments and best practices in the management of HIV/AIDS.

slide-5
SLIDE 5

HIV/AIDS in Practice Clinical Context Series

Target Audience

HIV/AIDS specialists, virologists, infectious disease specialists, primary care physicians, nurses, nurse practitioners, physician assistants, pharmacists, and

  • ther healthcare professionals involved in

the management of HIV/AIDS

slide-6
SLIDE 6

Upon successful completion of this educational program, participants should be able to: l Review the relevance and significance of the

activity in the broader context of clinical care

Activity Learning Objective

slide-7
SLIDE 7

l Statement of Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Projects In Knowledge and MedPage Today. Projects In Knowledge is accredited by the ACCME to provide continuing medical education for physicians.

CME Information: Physicians

slide-8
SLIDE 8

l Credit Designation

Projects In Knowledge designates this

educational activity for a maximum of 0.5 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Information

slide-9
SLIDE 9

l Credit for Family Physicians

MedPage Today "News-Based CME" has been reviewed and is acceptable for up to 2098 Elective credits by the American Academy of Family Physicians. AAFP accreditation begins January 1, 2013. Term of approval is for one year from this date. Each article is approved for 0.5 Elective credits. Credit may be claimed for one year from the date of each article.

CME Information: Physicians

slide-10
SLIDE 10

l Statement of Accreditation – Projects In Knowledge, Inc. (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. – Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227. – This activity is approved for 0.50 nursing contact hours. – There is no fee for this activity.

DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, CBRN, or PIK endorsement of any commercial product or service.

CE Information: Nurses

slide-11
SLIDE 11

Myron Cohen, MD

Associate Vice Chancellor for Global Health

  • J. Herbert Bate Distinguished Professor of Medicine,

Microbiology and Immunology Public Health Director, Institute for Global Health and Infectious Diseases Chief, Division of Infectious Diseases Director, Center for Infectious Diseases University of North Carolina (UNC) – Chapel Hill Chapel Hill, North Carolina

Discussant

slide-12
SLIDE 12

Myron Cohen, MD,

has disclosed no relevant financial relationships.

Disclosure Information

slide-13
SLIDE 13

Robert Jasmer, Associate Clinical Professor of Medicine, University of California, San Francisco; Michael Smith; and Dorothy Caputo, MA, BSN, RN, Nurse Planner, have disclosed that they have no relevant financial relationships or conflicts of interest with commercial interests related directly or indirectly to this educational activity. The staffs of Projects In Knowledge and MedPage Today have no relevant financial relationships or conflicts of interest with commercial interests related directly or indirectly to this educational activity.

Disclosure Information

slide-14
SLIDE 14

New Treatment Guidelines 2012

slide-15
SLIDE 15

Immediate Start to Therapy

l Treatment initiation previously guided

by CD4 cell count

l New guidelines urge offering treatment

to all newly diagnosed patients without regard to CD4 status

slide-16
SLIDE 16

Rationale for Change

l All patients may benefit from

antiretroviral therapy.

l Key randomized controlled trial showed

that antiretroviral therapy reduces risk

  • f HIV transmission.
slide-17
SLIDE 17

Considerations

l Patient must be willing, able to adhere

to therapy

l Adherence must be supported with

education

l Benefit of ART not clear in patients

already controlling HIV

l Benefit also unclear in patients without

symptoms

slide-18
SLIDE 18

Considerations

l Side effects of therapy l Concurrent conditions may affect

timing of initiation

slide-19
SLIDE 19

Recommended Initial Regimens

l Efavirenz/tenofovir/emtricitabine or

efavirenz plus abacavir/lamivudine in HLA-B*5701–negative patients high baseline viral load

l Darunavir/r plus tenofovir/emtricitabine,

atazanavir/r plus tenofovir/ emtricitabine, or atazanavir/r plus abacavir/lamivudine (in HLA-B*5701– negative patients high baseline viral load)

slide-20
SLIDE 20

Recommended Initial Regimens

l Raltegravir plus tenofovir/emtricitabine

slide-21
SLIDE 21

Considerations

l Ability of patients to tolerate certain

side effects

l Ability of regimen to lower viremia

rapidly

l Skill and experience of clinician still

important in managing HIV

slide-22
SLIDE 22

Summary

At the end of this activity, participants should understand:

  • That therapy should be offered to all patients newly

diagnosed with HIV regardless of CD4 count

  • That adherence to therapy has clinical benefits to the

patient despite side effects

  • That adherence to therapy renders a patient almost

completely noncontagious

  • That new options for treatment continue to evolve